European equities traded in the US as American depositary receipts were tracking lower Tuesday morning, declining 0.44% to 1,591.64 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biopharmaceutical companies DBV Technologies (DBVT) and Cellectis (CLLS), which climbed about 12% and 6%, respectively. They were followed by brewing company Anheuser-Busch InBev (BUD) and telecommunications company Nokia Oyj (NOK), which increased 1.9% and about 1%, respectively.

The decliners from continental Europe were led by biotech firm Evaxion (EVAX) and internet browser company Opera (OPRA), which shed 13% and 4.4%, respectively. They were followed by biopharmaceutical company Genfit (GNFT) and oil and gas company TotalEnergies (TTE), which lost 1.6% and 0.7%, respectively.

From the UK and Ireland, the gainers were led by biopharmaceutical companies NuCana (NCNA) and Adaptimmune Therapeutics (ADAP), which advanced 11% and 6.9%, respectively. They were followed by biopharmaceutical companies Akari Therapeutics (AKTX) and Amarin (AMRN), which increased 4.9% and 2.9%, respectively.

The decliners from the UK and Ireland were led by biotech firm Autolus Therapeutics (AUTL) and biopharmaceutical company Mereo BioPharma Group (MREO), which fell 4.5% and 3%, respectively. They were followed by cruise operator Carnival (CUK) and lender Lloyds Banking Group (LYG), which were down 1.8% and 1.4%, respectively.